HFSA 2026 Preview: Key Heart Failure Treatment Trends And Pipeline

HFSA 2026 at a glance At HFSA 2026, the question is where competition in heart…


ESC Congress 2026 preview covering ATTR-CM, hypertrophic cardiomyopathy, Factor XI inhibitors, lipid-lowering therapies and AI in cardiology.

ESC 2026 Preview: Cardiovascular Therapies and Competitive Trends

ESC at a glance At ESC Congress 2026, how will earlier patient identification,…


Cell_Gene_Therapy

Cell and Gene Therapy Today—November 13, 2025

This week’s cell and gene therapy update covers key developments including…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Braveheart Bio launches with $185M Series A

Lucid Diligence Brief: Braveheart Bio launches with $185M Series A Professional…


Privacy Preference Center